Studies have indicated that CXCL10 may promote the expression of IFN signature genes and TAA, potentially facilitating T cell infiltration into the tumor, ultimately enhancing PD-L1 and PD-1 blockade therapy (28). This evidence concerns the gene IFNA1 and neoplasm.